The Department has a Consultancy agreement with OMIX Research and Diagnostics Pvt. Ltd, Bangalore for the design, development and validation of Genomics based Diagnostic kits for the detection of Antibiotic resistant bacterial pathogens.
If successful, the proposed technologies would help detect the pathogens directly from patient's samples such as Urine and blood without the need for culture testing. It would help reduce the detection time and would be extremely useful in treating critically ill patients.
With tremendous progress in the analytical techniques like Next-Generation DNA sequencing, Tandem Mass spectrometry, Microarrays and Crystallography, there is an exponential increase in the genomics, proteomics, metabolomics, transcriptomics and structural data. This humongous amount of data is publicly accessible through the world wide web over various databases such as NCBI, EBI, DDBJ, PDB etc. Students are exposed to these databases through internet and are taught to integrate the data to understand the molecular mechanisms underlying various biological phenomena.
Using the Bioinformatics Infrastructural Facility established in the institute with the support from Department of Biotechnology, Govt. of India, efforts are directed towards integrating OMICS data to unravel the mechanisms underlying various diseases such as avascular necrosis, rheumatoid arthritis, glaucoma and atherosclerosis. Analysis and annotation of whole genome sequence data of clinically isolated multi-drug resistant bacteria is also carried out. Further, a computationally guided approach using molecular docking and molecular dynamics simulations is implemented to study the effect of physical and chemical environments on structure and function alterations in proteins and discovery of drugs for the treatment of diseases.
The project will help to understand whether secreted ATP has a role in the LPS and cytokine (TNFα and IFNγ) induced calcium response, expression of critical genes in inflammation, and activation of phagocytosis and chemotaxis. It will help understand the role of P2 receptors and downstream signaling events involved in the processes. Above all, it will also help us to delve into the details of the role of P2 receptors in a mouse model of MS and help identify possible therapeutic targets. It may be noted that some P2 receptor inhibitors are currently used as drugs, such as for thrombosis. Some are in phase II and phase III clinical trials for various cancers. We will validate these drugs for mouse model of MS. This work should reduce the lag period of these drugs for human MS trials. This project will have considerable impact on understanding and identifying possible therapeutic targets in other neuro-degenerative diseases. Many genes that are induced by exogenous treatment of ATP (Hsp90 and HDACs) are known therapeutic targets in various diseases and hence inhibiting up-regulation of these genes by targeting purinergic receptors will have a favorable therapeutic effect. These diseases include Parkinsons, retinal degeneration, Alzhimers and muscular dystrophy.
The research will create a system to automatically defend against zero-day polymorphic worms in communication networks by using machine learning algorithms. It will achieve this by setting up a pilot cyber security lab that can potentially be reproduced in the future to undertake further research in cyber-security.
Social relevance: To delineate the role of secreted ATP in the LPS and cytokine (TNFα and IFNγ) mediated calcium signalling in microglia.
To probe into the mechanism by which P2 receptors that are engaged by secreted ATP cause the cellular calcium response, expression of particular genes and activation of phagocytosis and chemotaxis which has implications for multiple sclerosis.
To understand the role of the P2 receptors in MS and evaluate them as possible targets for therapeutic intervention.
To elucidate the role of Microglia in multiple sclerosis and identify possible therapeutic targets.